{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:02:45Z","timestamp":1789225365975,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.leukres.2024.107640","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:03:04Z","timestamp":1734595384000},"page":"107640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"148","author":[{"given":"Moazzam","family":"Shahzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kashif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaib","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad Zaman","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashil","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Basharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hebishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jaglal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/17474086.2019.1598258","article-title":"An update on biology, diagnosis and treatment of primary plasma cell leukemia","volume":"12","author":"Musto","year":"2019","journal-title":"Expert Rev. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2024.107640_bib3","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1002\/cncr.24700","article-title":"Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004","volume":"115","author":"Ramsingh","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","article-title":"Primary plasma cell leukaemia","volume":"88","author":"Dimopoulos","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107640_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0145-2126(00)00102-8","article-title":"Primary plasma cell leukaemia: a report of 18 cases","volume":"25","author":"Costello","year":"2001","journal-title":"Leuk. Res"},{"issue":"12","key":"10.1016\/j.leukres.2024.107640_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107640_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20272","article-title":"Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature","volume":"78","author":"Saccaro","year":"2005","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/j.leukres.2024.107640_bib9","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"63","author":"Shahzad","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107640_bib10","unstructured":"H. Itonaga, J. Aoki, T. Ishikawa, 2017, Prognostic impavt of donor source on Allogeneic Hematopoietuc stem cell transplantation outcomes in adults with chronic myelononcytic leukemia Journal of the American Society of Blood and Marrow Transplantation 2017.."},{"issue":"12","key":"10.1016\/j.leukres.2024.107640_bib11","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2024.107640_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.leukres.2024.107640_bib13","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase ii study of the intergroupe francophone du my\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"issue":"3","key":"10.1016\/j.leukres.2024.107640_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"issue":"5","key":"10.1016\/j.leukres.2024.107640_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2024.107640_bib17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41409-018-0392-1","article-title":"Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs","volume":"54","author":"Gowda","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"45","key":"10.1016\/j.leukres.2024.107640_bib18","doi-asserted-by":"crossref","first-page":"79517","DOI":"10.18632\/oncotarget.18535","article-title":"The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.leukres.2024.107640_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107640_bib20","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.clml.2014.07.012","article-title":"Melphalan\/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia","volume":"14","author":"Landsburg","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.leukres.2024.107640_bib21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2024.107640_bib22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107640_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/j.bbmt.2020.08.035","article-title":"Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents","volume":"26","author":"Lemieux","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.leukres.2024.107640_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2024.107640_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/bloodadvances.2017010686","article-title":"Tandem autologous\/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma","volume":"1","author":"Green","year":"2017","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.leukres.2024.107640_bib26","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107640_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2024.107640_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma Cell Leukemia: Definition, Presentation, and Treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.leukres.2024.107640_bib30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bbmt.2019.11.028","article-title":"Age is a prognostic factor for the overall survival of patients with multiple myeloma undergoing upfront autologous hematopoietic stem cell transplantation","volume":"26","author":"Cordas Dos Santos","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"29","key":"10.1016\/j.leukres.2024.107640_bib31","article-title":"Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database","volume":"101","author":"Ge","year":"2022","journal-title":"Med. (Baltim. )"},{"issue":"2","key":"10.1016\/j.leukres.2024.107640_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020209","article-title":"The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells","volume":"10","author":"Papadhimitriou","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.leukres.2024.107640_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.leukres.2024.107640_bib34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107640_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hon.2820","article-title":"A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma","volume":"39","author":"Rocchi","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107640_bib36","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.938868","article-title":"Plasma cell leukemia with successful upfront venetoclax in combination with allogeneic transplantation","volume":"24","author":"Tang","year":"2023","journal-title":"Am. J. Case Rep."},{"issue":"15_","key":"10.1016\/j.leukres.2024.107640_bib37","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624002066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624002066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:01:11Z","timestamp":1736780471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624002066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0145212624002066"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107640","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107640"}}